[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-solid-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-solid-neoplasm":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,110,0,25,[9,41,63,89,111,134,160,178,200,230,249,268,288,306,326,342,359,438,466,486,511,529,563,590,626],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100191818","molecular-testing-for-the-md-anderson-cancer-center-personalized-cancer-therapy-program-100191818",false,"NCT01772771","Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program","Inclusion Criteria:\n\n* Patients must have histologically, radiographic, or cytologically documented cancer, suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign tumors may also be consented at the discretion of the attending physician if molecular profiling is felt to have potential clinical implications.\n* Patients must have the ability to understand and the willingness to sign a written informed consent document\n* Patients may be consented without confirming the amount and quality of archival diagnostic or residual tissue available. However, research testing will only be performed on patients who have sufficient archived diagnostic tissue or residual tissue banked in one of the authorized tissue banks at MD Anderson available to proceed with testing. The extent of testing may be modified based on amount of tissue available. If any new tissue acquisition including a biopsy and\u002For surgical resection etc. is being ordered for clinical care or another research study, or an operation is being performed testing can be ordered on that sample\n* Circulating cell-free deoxyribonucleic acid (cfDNA) Cohort: Circulating cell-free DNA next generation sequencing (NGS) testing will be performed with the Clinical Laboratory Improvement Act (CLIA)-certified Guardant360 panel (or equivalent) for select patients. This particular cohort of research collaboration will be supported by Guardant Health, Inc. at no charge to MD Anderson. Patients who are being considered for enrollment into clinical trials in the next 2 lines of therapy may be enrolled. Selected patients may have cfDNA, circulating RNA \u002Fexosome\u002Fcirculating tumor cell testing approaches performed on alternate platforms (eg Foundation ACT)","ALL",{"count":18,"type":19},12000,"ESTIMATED","OBSERVATIONAL","This study performs standardized testing of tumor tissue samples to learn which genes are mutated (have changed) in order to provide personalized cancer therapy options to cancer patients at MD Anderson. This may help doctors use testing information on tumors to identify clinical trials that may be most relevant to patients. Researchers may also use the information learned from this study to develop a database of the different kinds of mutations in cancer-related genes.",[23,24,25,26,27],"Glioma","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Solid Neoplasm","Melanoma","Sarcoma","RECRUITING","2026-08-20",{"date":31,"type":32},"2026-08-21","ACTUAL",{"date":34,"type":32},"2012-03-01",{"date":36,"type":19},"2033-03-01",{"name":38,"class":39},"M.D. Anderson Cancer Center","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100539463","validation-of-dna-methylation-markers-for-universal-and-site-specific-guided-cancer-detection-vanguard-study-100539463","NCT06304168","Validation of DNA Methylation Markers for Universal and Site-specific Guided Cancer Detection, VANGUARD Study","Validation of DNA Methylation Markers for the Universal and Site-Specific Guided Cancer Detection (the VANGUARD Study)","Inclusion Criteria:\n\n* Aim 1 Tissue\n\n  * Cases:\n\n    * Patient has a biopsy confirmed diagnosis of target histology\n    * Tissue samples from synchronous or metachronous primary cancers may be used as long as they are clearly of a different target organ.\n    * Tumors from patients with an underlying genetic disorder pre-disposing to cancer may be included as long as they are stratified from those without\n  * Controls:\n\n    * Patient does not have the diagnosis of target histology\n* Aim 2 Blood\n\n  * Cases:\n\n    * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)\n  * Controls:\n\n    * Patient does not have a documented diagnosis of cancer within 1 year following blood collections\n* Aim 3 Urine\n\n  * Cases:\n\n    * Patient has a biopsy confirmed diagnosis of target histology or radiographic criteria that are unequivocal for diagnosis (example, meets radiographic criteria for hepatocellular carcinoma)\n  * Controls:\n\n    * Patient does not have a diagnosis of the target histology\n\nExclusion Criteria:\n\n* Aim 1 Tissue\n\n  * Cases and Controls:\n\n    * Patient has had any transplants prior to tissue collection\n    * Patient has received chemotherapy class drugs within 5 years prior to tissue collection\n  * Cases:\n\n    * Patient has had radiation to the current target lesion prior to tissue collection\n    * Patient has multi-centric\u002Fmulti-focal breast cancer with differing genetic profiles (ER\u002FHER2\u002FPR status differ; if multiple masses are present and not all are tested then exclude patient)\n    * Patient has bilateral breast cancer\u002FDuctal carcinoma in situ (DCIS)\n* Aim 2 Blood\n\n  * Controls:\n\n    * Patient has known cancer prior to current sample acquisition (not including basal cell or squamous cell skin cancers) (if patient has not been seen or if information is not available, the patient is still eligible)\n  * Cases:\n\n    * Patient has known cancer outside of the target cancer 5 years prior to blood collection (not including basal cell or squamous cell skin cancers)\n    * Patient has received chemotherapy class drugs in the 5 years prior to blood collection\n    * Patient has had any prior radiation therapy to the target lesion prior to blood collection\n    * Patient has had an intervention to completely remove current target pathology\n    * The current target pathology is a recurrence\n    * Patient has had a biopsy to the target organ and\u002For lesion within 3 days before blood collection\n* Aim 3 Urine\n\n  * Patient has known cancer outside of the target cancer 5 years prior to urine collection (not including basal cell or squamous cell skin cancers)\n  * Patient has received chemotherapy class drugs in the 5 years prior to urine collection\n  * Patient has had any prior radiation therapy to the target lesion prior to urine collection\n  * Patient has had a biopsy to the target organ and\u002For lesion within 3 days before urine collection\n  * The current target pathology is a recurrence\n  * Patient has chronic indwelling urinary catheter\n  * Patient has had a urinary tract infection within the 14 days prior to sample collection\n  * If patient does not have a primary bladder, ureter or urethral cancer, patient has a history of bladder ureter, or urethral cancer\n  * Cases:\n\n    * Patient has had an intervention to completely remove current target pathology\n    * The current target pathology is a recurrence",true,"18 Years",{"count":51,"type":19},6150,"This study explores the potential value of a new blood test approach for early detection of cancer.",[54,25],"Hematopoietic and Lymphatic System Neoplasm","2026-08-19",{"date":29,"type":32},{"date":58,"type":32},"2019-05-13",{"date":60,"type":19},"2028-05-15",{"name":62,"class":39},"Mayo Clinic",{"id":64,"slug":65,"hasResults":12,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":40},"100561203","wearable-activity-tracking-to-curb-hospitalizations-100561203","NCT06587100","Wearable Activity Tracking to Curb Hospitalizations","Wearable Activity Tracking to Curb Hospitalizations (WATCH)","WATCH","Inclusion Criteria:\n\n* Age \\>= 18.\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 or Karnofsky Performance Scale (KPS) ≤ 50%.\n* Able to understand study procedures and to comply with them for the entire length of the study.\n* Ability of individual or legal guardian\u002Frepresentative to understand a written informed consent document, and the willingness to sign it.\n* Diagnosis of invasive malignancy.\n* Able to ambulate independently (without the assistance of a cane or walker).\n* Planned treatment with fractionated external beam radiotherapy over at least 5 days (no fractional requirement).\n* Not a previous participant on this protocol for subsequent courses.\n\nExclusion Criteria:\n\n* Participants bound to a wheelchair.\n* Participants unable to ambulate independently (needing assistance of cane or walker).",{"count":72,"type":19},260,"This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.",[75,25,76],"Hematopoietic Neoplasm","Lymphatic System Neoplasm",[78,79,80],"Activity tracking","Hospitalization prevention","Artificial Intelligence (AI) modelling","2026-08-18",{"date":29,"type":32},{"date":84,"type":32},"2025-04-07",{"date":86,"type":19},"2027-12-31",{"name":88,"class":39},"University of California, San Francisco",{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100343329","phase-3-pre-operative-or-post-operative-stereotactic-radiosurgery-in-treating-patients-with-operative-metastatic-brain-tumors-100343329","NCT03750227","Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors","Pre-Operative vs. Post-Operative Stereotactic Radiosurgery for Operative Metastatic Brain Tumors","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Histological or cytological confirmation of solid tumor malignancy and\u002For clinical history of known or suspected metastatic disease with an intraparenchymal brain tumor consistent with brain metastasis based on clinical and radiologic findings\n* Clinical indication for surgical resection of one brain metastasis based on neurosurgery recommendation and patient deemed a surgical candidate\n* Clinical indication and plan for stereotactic radiosurgery to all known brain lesions requiring treatment (=\\\u003C 10 metastases)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\\\u003C 2\n* Provide written informed consent or have a legally authorized representative who is responsible for the care and well-being of the potential study participant, provide consent\n* Willing to continue follow-up visits, either at the enrolling institution or with a local medical doctor as clinically appropriate, and according to the study timeline. Clinical notes and digital copies of imaging must be provided to the enrolling site if follow-up is done externally\n\nExclusion Criteria:\n\n* Any of the following:\n\n  * Pregnant women\n  * Nursing women\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy. \\* NOTE: Patients known to be HIV, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Prior open neurosurgery for malignancy\n* Known or clinically suspected primary germ cell tumor, small cell carcinoma, or lymphoma\n* History of whole brain radiation therapy (WBRT)\n* Known allergy to gadolinium, pacemaker, or other contraindication such as metal implant that is not safe for MRI. Patients with MRI-compatible implants including MRI compatible pacemakers are eligible\n* Leptomeningeal metastasis\u002Fdisease\n* A brain metastasis that is located =\\\u003C 5 mm of the optic chiasm\n* Any brain metastasis \\> 5 cm in size\n* \\> 10 brain metastases\n* Indication for surgical resection of \\>= 2 brain metastases\n* Indication for long-term (anticipated greater than 4 weeks) 4 mg dexamethasone equivalent of steroids or bevacizumab\n* Actively enrolled on another brain metastases trial that is assessing the efficacy of either radiation or surgical interventions",{"count":97,"type":19},140,"INTERVENTIONAL",[100],"PHASE3","This phase III trial studies the side effects and how well stereotactic radiosurgery (SRS) works before or after surgery in patients with tumors that has spread to the brain or that can be removed by surgery. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.",[25,103],"Metastatic Malignant Neoplasm in the Brain",{"date":55,"type":32},{"date":106,"type":32},"2018-11-19",{"date":108,"type":19},"2030-11-08",{"name":62,"class":39},4,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":48,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":98,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":133},"100538786","cost-communication-and-financial-navigation-in-cancer-patients-costcom-100538786","NCT06295367","Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)","Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients","Inclusion Criteria:\n\n* NON-PATIENTS PARTICIPANTS: Participant must speak English\n* NON-PATIENTS PARTICIPANTS: Participant must be employed at National Cancer Institute Community Oncology Research Program (NCORP) site for at least six months\n* NON-PATIENTS PARTICIPANTS: Participant must be able to provide informed consent to participate in this study\n* NON-PATIENTS PARTICIPANTS: Participant must be one of the following:\n\n  * A study coordinator with a role involving use of CostCOM intervention price transparency and financial navigation platform\n  * A practice oncology provider (i.e., physician or mid-level), or\n  * A practice financial counselor, social workers, financial navigators, or pharmacist who have provided care or been in contact (in the last 3 months) to a patient who was assigned to the CostCOM arm, and who completed the at least 6 month study follow-up\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be ≥ 18 years of age\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be fluent in written and spoken English OR patient must be fluent in written and spoken Spanish\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must be within 120 days of a new diagnosis of any solid cancer of any stage at the time of Step 0\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have had their first medical oncology visit at the time of Step 0\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have initiated oral or intravenous (IV) cancer systemic therapy or have received a prescription order with stated intent to initiate within 30 days following Step 0 consent\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not have indolent cancer undergoing observation alone (i.e., active surveillance)\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patients must not be receiving palliative or hospice care alone\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be undergoing curative surgery alone or radiation therapy alone. (Must be receiving systemic therapy), unless they are receiving systemic therapy\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must confirm that they intend to receive their care or monitoring at one of the participating NCORP practices\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must have the ability to understand and the willingness to sign a written informed consent document.\n\n  * Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and\u002For family member available are not eligible\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not have an Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3, OR\n\n  * Patient must not be deemed medically unable to participate in the study by the study investigators or an oncology clinician (i.e., referral to hospice)\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in treatment clinical trials where cancer systemic therapy is provided at no cost to the patient\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in EAQ221CD or S1912CD given financial navigation is offered as part of these two trials.\n\n  * NOTE: If S1912CD is activated in a participating practice, S1912CD should be offered first to patients with metastatic cancer meeting eligibility criteria for S1912CD. Only if a patient is not eligible or not interested in participating in S1912CD, the EAQ222CD can be offered. For early stage cancer, EAQ222CD can be offered first given S1912CD does not enroll patients with early stage cancer\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 0 (OPEN SCREENING REGISTRATION): Patient must not be enrolled in other clinical trials where OOPC communication or financial navigation (i.e., professional guidance to identify financial assistance programs to alleviate cost of care) is being offered as part of the trial\n\n  * NOTE: If a trial is offering financial counseling alone without financial navigation patients are allowed to co-enroll\n  * NOTE: Gift cards for survey completion, or parking passes are not considered financial navigation\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must meet all the eligibility criteria for step 0\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have signed a written informed consent form\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patient must have a completed baseline survey in ECOG American College of Radiology Imaging Network Systems for Easy Entry of Patient Reported Outcomes (EASEE-PRO) within 30 days of the date of OPEN registration and consent (step 0)\n* PATIENT ELIGIBILITY CRITERIA FOR STEP 1 (OPEN RANDOMIZATION): Patients must have initiated their cancer treatment (i.e., IV or oral systemic therapy) either before or within 30 days of the date of OPEN registration and consent (step 0)",{"count":119,"type":19},760,[121],"NA","This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, education and connections to appropriate resources to reduce financial barriers to healthcare and minimize financial stress and burden. CostCOM may improve adherence to care and decrease financial burden in patients with cancer.",[25],"2026-08-17",{"date":55,"type":32},{"date":127,"type":32},"2024-02-29",{"date":129,"type":19},"2027-12-01",{"name":131,"class":132},"ECOG-ACRIN Cancer Research Group","NETWORK",391,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":98,"phases":143,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":159},"100525787","phase-2-testing-the-use-of-neratinib-or-the-combination-of-neratinib-and-palbociclib-targeted-treatment-for-her2-solid-tumors-a-combomatch-treatment-trial-100525787","NCT06126276","Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)","A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4\u002F6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial","Inclusion Criteria:\n\n* Patient must have enrolled onto EAY191 and must have been given a treatment assignment to ComboMATCH to EAY191-N5 based on the presence of an actionable mutation as defined in EAY191\n* Patients must have a HER2 amplified solid tumor except breast cancer.\n\n  * If IHC is 0 or 1+, patient (pt) is NOT ELIGIBLE regardless of in situ hybridization (ISH)\u002FFISH or next generation sequencing (NGS) status\n  * If IHC is 3+, pt IS ELIGIBLE regardless of ISH\u002FFISH or NGS status\n  * If IHC is 2+, ISH\u002FFISH OR NGS must be positive for the patient to be ELIGIBLE. Otherwise, pt is NOT ELIGIBLE\n  * If IHC is unknown and…\n\n    * ISH\u002FFISH is positive, independent of NGS results, the patient IS ELIGIBLE\n    * ISH\u002FFISH is negative and NGS positive with ≥ 7 copies, the patient IS ELIGIBLE\n* Patients must have recurrent or persistent disease\n* No known evidence of RB1 loss or deletion including copy number loss or deleterious mutation\n* Patients must have disease that can be safely biopsied and agree to a pre-treatment biopsy or, if disease cannot be safely biopsied, have archival tissue available from within 12 months prior to the date of registration on the ComboMATCH Registration Trial (EAY191)\n* Patients must have measurable disease based on RECIST 1.1. A second measurable lesion outside of the biopsiable lesion is required\n* Patients with treated brain metastases are eligible if follow up brain imaging after central nervous system (CNS) directed therapy shows no evidence of progression for 3 months or more and patient is not on steroids and is asymptomatic\n* No known leptomeningeal disease\n* Patients may have received up to 5 prior lines of systemic therapy\n* Prior therapy with trastuzumab or pertuzumab, either alone or in combination, antibody drug conjugates (ADC) such as DS8201a or T-DM1 is allowed\n* No prior therapy with HER2 targeting tyrosine kinase inhibitors (TKI) such as neratinib or tucatinib\n* No prior therapy with CDK4\u002F6 inhibition\n* No cancer directed therapy within 3 weeks prior to registration. For oral therapy, the washout can be reduced to greater than or equal to 5 half lives of the drug. No HER2 targeting ADCs within 30 days prior to registration\n* Age ≥ 18\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2\n* Not pregnant and not nursing\n* Absolute neutrophil count (ANC) ≥ 1,500 cells\u002Fmm\\^3\n* Platelets ≥ 100,000 cells\u002Fmm\\^3\n* Hemoglobin ≥ 9 g\u002Fdl (Note: The use of transfusion or other intervention to achieve hemoglobin (Hgb) ≥ 9 g\u002Fdl is acceptable)\n* Creatinine clearance (CrCL) of ≥ 30 mL\u002Fmin by the Cockcroft-Gault formula\n* Total bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x institutional ULN may be enrolled)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x institutional upper limit of normal (ULN)\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better\n* No active infection requiring parenteral antibiotics\n* No current evidence of intra-abdominal abscess, abdominal\u002Fpelvic fistula (not diverted), gastrointestinal perforation, gastrointestinal (GI) obstruction, and\u002For need for drainage nasogastric or gastrostomy tube\n* No current evidence of malabsorption or chronic diarrhea or any other significant gastro-intestinal disease (e.g gastrectomy, ileal bypass, Crohn's disease, gastroparesis), associated with moderate to severe diarrhea (grade 2 or more) or inability to tolerate oral therapy\n* No lung disease causing dyspnea at rest\n* No interstitial lung disease with ongoing signs and symptoms at the time of registration\n* No history of allergic reaction to the study agents, compound of similar chemical or biologic composition of the study agents or any of their excipients",{"count":142,"type":19},70,[144],"PHASE2","This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.",[147,25,148,149],"Malignant Female Reproductive System Neoplasm","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Solid Neoplasm","2026-08-15",{"date":81,"type":32},{"date":153,"type":32},"2024-05-07",{"date":155,"type":19},"2027-02-20",{"name":157,"class":158},"National Cancer Institute (NCI)","NIH",189,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":110},"100543232","biomarkers-to-predict-cancer-therapy-related-cardiotoxicity-100543232","NCT06353191","Biomarkers to Predict Cancer Therapy-related Cardiotoxicity","Biomarkers to Predict Cancer Therapy-Related Cardiotoxicity","Inclusion Criteria:\n\n* 18 years of age or older\n* Treated for any malignancy with any type of chemotherapy including oral, parenteral therapy and immunotherapy\n* One of the following:\n\n  * Diagnosed with cardiotoxicity defined as; cardiomyopathy, symptomatic heart failure, asymptomatic reduced systolic function, acute coronary syndrome, myocardial infarction, critical limb ischemia, cardiac arrhythmias or myocarditis possibly related to prior cancer treatment\n  * Completed chemotherapy with no cardiotoxicity at least two years post treatment\n  * Patients with cancer who will be initiating systemic therapy with potentially cardiotoxic medications. This will include chemotherapy, immunotherapy, targeted therapy that have been associated with cardiac toxicity\n* An understanding of the protocol and its requirements, risks, and discomforts\n* The ability and willingness to sign an informed consent\n\nExclusion Criteria:\n\n\\- Inability on the part of the patient to understand the informed consent or be compliant with the protocol",{"count":168,"type":19},693,"This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.",[54,25],"2026-08-14",{"date":81,"type":32},{"date":174,"type":32},"2019-05-03",{"date":176,"type":19},"2031-12-31",{"name":62,"class":39},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":98,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":40},"100652379","an-artificial-intelligence-powered-supportive-care-chatbot-to-address-the-supportive-care-needs-of-young-adult-cancer-survivors-100652379","NCT07772596","An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors","Feasibility, Usability, and Acceptability of an AI-Powered MASCC Supportive Care Platform Among Young Adults With Cancer","Inclusion Criteria:\n\n* 18 - 39 years old\n* Able to speak\u002Fread English\n* Completed primary cancer treatment (e.g., surgery, radiation, chemotherapy, immunotherapy) at least one month prior to the time of consent. Although, participants will be eligible if they are receiving maintenance treatments\n* Report at least one moderate to severe symptom, side effect, or supportive care concern from cancer or its treatment\n* Able to access Wi-Fi\u002Finternet\n* Willing to complete surveys electronically\n\nExclusion Criteria:\n\n* Completed cancer treatment more than three years ago","39 Years",{"count":187,"type":19},30,[121],"This clinical trial studies whether an artificial intelligence (AI)-powered supportive care chatbot is helpful for addressing the supportive care needs of young adult cancer survivors. Young adult cancer survivors often experience ongoing and distressing symptoms following treatment, including extreme tiredness and lack of energy, anxiety, and difficulty sleeping. Young adult cancer survivors report a variety of strategies to self-manage these symptoms; however, there remains a gap in targeted interventions focused on the needs in young adult survivors. The AI-powered supportive care chatbot is designed to provide evidence-based information on supportive care for young adult cancer survivors. Users interact with the chatbot by entering free-text questions or selecting from predefined topics to receive tailored educational responses related to supportive care across the cancer continuum, including treatment effects, symptom management, care transitions, and life after cancer. The AI-powered supportive care chatbot may be an effective way to help address the supportive care needs of young adult cancer survivors.",[54,25],"NOT_YET_RECRUITING","2026-08-13",{"date":55,"type":32},{"date":195,"type":19},"2026-10-01",{"date":197,"type":19},"2028-10-01",{"name":199,"class":39},"University of Michigan Rogel Cancer Center",{"id":201,"slug":202,"hasResults":12,"nctId":203,"briefTitle":204,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":48,"sex":16,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":98,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},"100592628","the-vanguard-study-testing-a-new-way-to-screen-for-cancer-100592628","NCT06995898","The Vanguard Study: Testing a New Way to Screen for Cancer","Inclusion Criteria:\n\n* Ages 45-75 years old\n* Agree to provide blood samples for possible MCD testing at enrollment and at 1 year following enrollment\n* Agree to allow collection of information from their medical records for study-related purposes\n* Understand and be able to complete informed consent and participant questionnaires in English, Spanish, or Arabic\n\n  * Note: Eligibility for Spanish and Arabic languages are at the Hub's discretion\n\nExclusion Criteria:\n\n* Solid malignant tumor or blood cancer diagnosis, with or without treatment, within the last 5 years\n\n  * Note: Persons with a history of in situ cancers (e.g., ductal carcinoma in situ of the breast, cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ) or nonmelanoma skin cancer are eligible. Persons with a history of prostate cancer that has not been treated are not eligible, regardless of when the diagnosis occurred\n* Ongoing cancer diagnostic work-up\n* Ongoing participation in another study of an investigational cancer screening test or technology not currently utilized in routine clinical practice\n* Currently breastfeeding or pregnant, or planning to become pregnant in the next year\n* History of solid organ or hematopoietic transplantation at any time, or blood transfusion within the last 30 days","45 Years","75 Years",{"count":209,"type":19},24000,[121],"The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for multiple cancers simultaneously. There is a need to understand how MCDs may work as cancer screening tools. The goal of cancer screening is to reduce the burden of cancer by identifying cancers before they show symptoms or signs, when treatment is likely to be most effective. In this study, adults aged 45-75 without cancer will be randomly assigned to one of 3 groups: 2 separate MCD test groups or a control group. These two MCD tests will not be compared to each other but will be compared to cancers detected in the control group. This study will provide early information on how well MCD tests perform as cancer screening tools. It will also help researchers understand how patients and their doctors make decisions about their care when the MCD test result comes back as normal (negative) or abnormal (positive).",[213,214,215,216,217,218,219,25,220,221,222],"Bladder Carcinoma","Breast Carcinoma","Colorectal Carcinoma","Esophageal Carcinoma","Gastric Carcinoma","Liver Carcinoma","Lung Carcinoma","Ovarian Carcinoma","Pancreatic Carcinoma","Prostate Carcinoma",{"date":171,"type":32},{"date":225,"type":32},"2025-06-18",{"date":227,"type":19},"2029-06-30",{"name":157,"class":158},40,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":98,"phases":238,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":242,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":248},"100530249","early-phase-1-alteplase-through-an-indwelling-pleural-catheter-for-the-management-of-symptomatic-septated-malignant-pleural-effusion-100530249","NCT06184321","Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion","A Randomized Trial of Alteplase Versus Placebo Through an Indwelling Pleural Catheter for Management of Symptomatic Septated MPE","Inclusion Criteria:\n\n* Referral to pulmonary services for inability to drain fully via IPC\n* Presence of a symptomatic septated pleural effusion\n* A pleural effusion of significant moderate to large volume based on:\n\n  * Chest radiograph: effusion filling \\>= 1\u002F3 of the hemithorax, or\n  * Computed tomography (CT)-scan: AP depth of the effusion \\>= 1\u002F3 of the AP dimension on the axial image superior to the hemidiaphragm, including atelectatic lung surrounded by effusion, or\n  * Ultrasound: effusion spanning at least three intercostal spaces, with a \\>= 3 cm in at least one intercostal space, while the patient sits upright\n* Age \\> 18\n* Borg score \\>= 3\n* Absence of a blocked IPC as demonstrated by a flush with 20 cc of saline x1 without resistance\n* Presence of septated effusion based on ultrasound (US) and chest CT\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Study subject has any disease or condition that interferes with safe completion of the study including:\n\n  * Uncorrectable coagulopathy based on criteria followed by cardiopulmonary center for procedures.\n  * Active bleeding\n  * Known allergic reaction to thrombolytics\n* Pleural effusion is smaller than expected on bedside pre-procedure ultrasound\n* No septations and\u002For no loculations on bedside pre-procedure ultrasound\n* Patient is asymptomatic\n* Blocked IPC as determined by saline flush",{"count":187,"type":19},[239],"EARLY_PHASE1","This study investigates whether alteplase can help to improve pleural fluid drainage and dyspnea (breathlessness) in patients with non-draining malignant pleural effusion. Alteplase helps dissolve blood clots and is used to treat heart attacks, strokes, and clots in the lungs. Alteplase may help to control symptoms of breathlessness.",[24,25],{"date":124,"type":32},{"date":244,"type":32},"2023-08-17",{"date":246,"type":19},"2027-02-02",{"name":38,"class":39},2,{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":98,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":40},"100422139","expressive-writing-for-the-management-of-stress-in-cancer-survivors-100422139","NCT04776941","Expressive Writing for the Management of Stress in Cancer Survivors","COVID-19: A Virtual Feasibility Study to Manage Stress","Inclusion Criteria:\n\n* At least 18 years old\n* Have a diagnosis of cancer within the past 3 years\n* Are able to speak and read in English\n* Have access to a computer or smart phone with internet connection\n* All disease sites and all cancer stages are eligible for enrollment\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Non-English speakers will be excluded because this is a feasibility study that will enroll only a limited number of participants",{"count":257,"type":19},414,[121],"This clinical trial evaluates the effect of expressive writing for the management of stress in cancer survivors. Cancer diagnosis and treatment are associated with increased stress in cancer survivors related to concerns about family, career, relationships, finances, side effects of treatment, and death. This stress can be further exacerbated by social upheavals such as the COVID-19 pandemic. For safety reasons, many patients are isolated with restricted access to in-person health care and reduced social interaction with family and friends. Together with the economic uncertainties that come with this pandemic, these factors are likely to increase cancer survivors' stress levels. Expressive writing may provide a medium through which cancer survivors confront stressors and find meaning in their experience. The goal of this trial is to learn more about the experiences of cancer survivors during stressful times.",[24,25],"2026-08-12",{"date":171,"type":32},{"date":264,"type":32},"2020-08-07",{"date":266,"type":19},"2028-12-31",{"name":38,"class":39},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":207,"enrollmentInfo":275,"targetDuration":4,"studyType":98,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":40},"100579650","phase-2-psilocybin-with-psychotherapy-for-improving-chronic-pain-in-cancer-patients-requiring-opioids-100579650","NCT06827054","Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids","Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 75 years old\n* Diagnosis of active cancer, any stage\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n* Estimated prognosis of ≥ 3 months at the time of enrollment, determined by participant's primary oncologist or palliative physician\n* Diagnosis of moderate to severe pain (reported average pain score ≥ 4 on the 11-point Numerical Rating Scale) that is chronic (≥ 3 months) and secondary to cancer or cancer treatment\n* Pain regimen has been escalated to opioid therapy\n\n  * Participants must be on stable pain regimen for at least one month prior, with no intention to adjust pain regimen during the study period\n* Participants must be ≥ 4 weeks beyond treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation). Participants may otherwise receive cancer-directed treatment throughout the study period\n* Have no known procedures\u002Ftreatments scheduled in advance that would prohibit patient from completing or significantly delaying completion of the study\n\n  * The participant has no vacations or plans to be out of town during their study enrollment\n* Participants must not plan for additional treatments\u002Fprocedures that, in the opinion of the study physician, would significantly affect outcomes related to pain and physical function (e.g., surgery or radiation) for ≥ 4 weeks following psilocybin treatment initiation. Participants may otherwise receive cancer-directed treatment throughout the study period\n* No use of other illicit substances (excluding cannabis) within the past year based on self-report at screening and routine urine toxicology screen\n* Participants must be able to read, write, and speak English\n* Participants must be able to swallow pills\n* Agree to refrain from using any unprescribed psychoactive drugs, including alcoholic beverages, ≤ 24 hours of before each psilocybin administration. Exceptions include:\n\n  * Daily use of caffeine or nicotine\n  * Prescribed benzodiazepine medications and non-benzodiazepine sleeping medications will be allowed to continue through the study period for participants who have been on a stable dose of such a medicine for ≥ 6 weeks prior to screening\n* Participants using cannabis, including legal cannabis, for any purpose must agree to refrain from use beginning at two weeks before dosing and one week following completion of dosing (7-8 weeks total, dependent on frequency of prior use)\n\n  * Participants will not be withdrawn from the trial for a positive cannabis result during the initial screening drug test. However, participants who test positive for cannabis at the second drug test on visit 10 will be withdrawn from the trial\n* Participants must agree to be driven home after each experimental session and not drive or operate heavy machinery ≤ 16 hours of ingesting psilocybin\n* Participants must provide an emergency contact (relative, spouse, close friend, or other support person) willing and able to be reached by the investigators if the participant is unreachable by study staff or in an emergency\n* The participant agrees to take part in all study procedures, including the assessments, psychological evaluations, and dosing day requirements\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Participants who are pregnant or breast-feeding\n* Participants of childbearing potential who decline to use a highly effective dual contraceptive method for the duration of the study\n* Participants with a condition impairing oral intake or digestive absorption\n* Cognitive impairment as defined by Montreal Cognitive Assessment (MOCA) score \\\u003C 23\n* Medical conditions or serious abnormalities of complete blood count, chemistries, or electrocardiography (ECG) that in the opinion of the study physician would preclude safe participation in the trial. Some examples include: congestive heart failure, valvular heart disease, recent acute myocardial infarction or evidence of ischemia, clinically significant arrhythmias (e.g., ventricular fibrillation, torsades) or clinically significant ECG abnormality (e.g. corrected QT interval using Fridericia's Correction Formula \\[QTcF\\] interval \\> 450 in males and \\> 470 in females), uncontrolled hypertension (systolic blood pressure \\[BP\\] ≥ 140 or diastolic BP ≥ 90 on three separate occasions), congenital long QT syndrome, renal dysfunction (i.e. creatinine clearance \\[CrCl\\] \\\u003C 40 mL\u002Fmin), liver cirrhosis or hepatic dysfunction (indicated by gamma-glutamyltransferase \\[GGT\\], aspartate aminotransferase \\[AST\\], or alanine aminotransferase \\[ALT\\] \\> 3 x ULN \\[upper limit of norm\\] or total bilirubin \\[bili\\] \\> 3.0 mg\u002Fdl, or Child Pugh over class C), paraneoplastic syndrome, respiratory failure, dementia, delirium, known cerebral aneurysm, seizure disorder, stroke\u002Ftransient ischemic attack (TIA) in past year, cancer with known central nervous system (CNS) involvement, previously treated brain metastasis, or other major CNS disease\n* Participants who have a personal history of, or a current diagnosis of the following: primary psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1 or history of or current dissociative identity disorder\n* Participants who have an ongoing substance use disorder (defined as active in the past year)\n* Participants with first-degree relatives with schizophrenia or bipolar disorder may be eligible depending on their age and personal and family psychiatric history. The decision will be made by the principal investigator and study psychiatrist or on-call psychiatric provider based on risk assessment\n* Active suicidal behavior (interrupted or aborted attempt; preparatory acts) as assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) connotating either passive or active suicidal intent; OR one of the following:\n\n  * History of suicide attempt(s) within the past year (≤ 365 days)\n  * Have any suicidal ideation or thoughts, in the opinion of the study physician or principal investigator (PI), that presents a serious risk of suicidal or self-injurious behavior\n* Any contraindications to undergoing an fMRI scan, including having metal implants or metal fragments in the body\n* Participants who have hypersensitivity to the ingredients of the IMP (Investigational Medicinal Product) listed below:\n\n  * Indol alkaloids including psilocybin and psilocin\n  * Constituents of Psilocybe cubensis including protein, fats, carbohydrates, ergosterols, beta-glucan, and polyphenols\n  * Hydroxypropyl methylcellulose (HPMC) capsules\n* Participants who are taking medications with significant potential to interact with study medications will be exclusionary if they cannot be tapered. The taper interval will be at least five times the half-life. These medications include the following:\n\n  * Selective serotonin reuptake inhibitors (SSRIs)\n  * Serotonin and norepinephrine reuptake inhibitors (SNRIs)\n  * Tricyclic antidepressants (TCAs)\n  * Efavirenz\n  * Serotonin-acting dietary supplements (i.e., 5-hydroxy-tryptophan or St. John's wort)\n  * Centrally acting serotonergic agents (e.g., monoamine oxidase \\[MAO\\] inhibitors)\n  * Antipsychotics for a psychiatric disorder (e.g., first and second generation)\n\n    * Antipsychotics that are utilized for nausea, insomnia, or other non-psychiatric condition will be permitted, but patients will be asked to refrain from use 8 hours prior to dosing sessions\n  * Mood stabilizers (e.g., lithium, valproic acid)\n  * Aldehyde dehydrogenase inhibitors (e.g., disulfiram)\n  * Significant inhibitors of UGT 1A9 or UGT 1A10\n* Use of serotonergic hallucinogens (e.g., psilocybin, lysergic acid diethylamine \\[LSD\\]) within the past 12 months or significant lifetime use (\\> 25 uses)\n* Those with a history of prior violent and\u002For drug-related felonies\n* Those currently incarcerated will be excluded\n* Unwilling or unable to follow protocol requirements\n* Any social circumstance which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug",{"count":276,"type":19},20,[144],"This phase II trial studies whether psilocybin with psychotherapy is safe and if it works for improving chronic pain in cancer patients who require opioids to manage their pain. Psilocybin is taken from the mushroom Psilocybe mexicana. Psilocybin acts on the brain to cause hallucinations (sights, sounds, smells, tastes, or touches that a person believes to be real but are not real). This may impact a patient's \"total pain\", a view that accounts for the psychological, spiritual, and social factors that contribute to their experience of pain. Psychotherapy uses methods such as discussion, listening, and counseling to help patients change the way they react to environmental triggers that may cause a negative reaction. Giving psilocybin with psychotherapy may be safe and helpful for improving chronic pain in cancer patients who require opioids to manage their pain.",[54,25],"2026-08-10",{"date":261,"type":32},{"date":283,"type":19},"2026-09-15",{"date":285,"type":19},"2027-05-05",{"name":287,"class":39},"Roswell Park Cancer Institute",{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":98,"phases":296,"briefSummary":297,"conditions":298,"keywords":4,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":248},"100575396","a-pilot-unrestricted-payment-program-for-early-stage-cancer-patients-the-payment-trial-100575396","NCT06771739","A Pilot Unrestricted Payment Program for Early-stage Cancer Patients: the PAYMENT Trial","Preventing Financial Adversity Among Early-Stage Cancer Patients Through Unrestricted Cash (PAYMENT) Pilot Study","Inclusion Criteria:\n\n* Age \\>= 18\n* Ability to understand English\n* Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants\n* Within 90 days of a non-metastatic or early-stage solid tumor receiving or rescheduled to receive treatment in the neoadjuvant, adjuvant or definitive setting for curative intent. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2\n* Current cancer patient at PeaceHealth (Southwest Medical Center or St. Joes)\n* Not current Medicaid enrollee\n* Not enrolled in hospice\n* Screens positive for financial fragility",{"count":276,"type":19},[121],"This clinical trial studies whether an unrestricted cash payment program can be used to improve financial and clinical outcomes in early-stage cancer patients with financial concerns. A cancer diagnosis can have poor financial outcomes, and the cost of cancer treatment can lead to high medical debt and financial hardships for the patient and family. Financial hardship during cancer treatment is associated with adverse outcomes including poorer quality of life, lower treatment compliance, more aggressive use of hospital-based care, and worse survival. Newly diagnosed cancer patients with financial concerns may avoid treatment entirely so that they can continue to work and maintain income, provide for their families, or pay rent. An unrestricted cash payment program provides patients with a preloaded cash card once monthly. The patients can choose what to use the card to pay for and may include items like food, rent, or utilities. This provides a period of guaranteed income for the patients and may prevent them from falling into poverty and improve financial and clinical outcomes.",[25],{"date":261,"type":32},{"date":301,"type":19},"2026-09-01",{"date":303,"type":19},"2026-12-01",{"name":305,"class":39},"Fred Hutchinson Cancer Center",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":98,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":40},"100602667","a-virtual-community-health-educator-for-increasing-clinical-trial-referrals-among-cancer-patients-and-their-caregivers-100602667","NCT07126496","A Virtual Community Health Educator for Increasing Clinical Trial Referrals Among Cancer Patients and Their Caregivers","Precision Clinical Trial Recruitment to Promote Cancer Health Equity Across Florida (Aims 2 & 3)","Inclusion Criteria:\n\n* Individuals Diagnosed with Cancer\n\n  * 18 years or older\n  * Must have received a cancer diagnosis at any point in your life\n  * Able to understand English or Spanish\n* Care Partners\n\n  * Must be a care partner (also known as caregiver, carer, supporter, helper, aide, assistant, companion, attendant, advocate, or family caregiver) of an adult who has received a cancer diagnosis\n  * Must be actively involved in the decision-making process OR care of a person diagnosed with cancer\n  * Must be 18 years or older\n\nExclusion Criteria:\n\n* Self-reported: people who are currently or have been in a cancer clinical trial within the last 3 years",{"count":314,"type":19},2000,[121],"This clinical trial studies how well a virtual community health educator (vCHE) works in increasing clinical trial referrals for patients with cancer and their caregivers. Low enrollment of underrepresented and underserved populations in cancer clinical trials has led to disparities in intervention development and implementation. One approach to recruiting diverse populations to cancer clinical trials is community health educators. However, community health educator interventions are costly and difficult to implement. vCHEs are photo-realistic virtual agents that provide personalized guidance and support to users. They are designed to mimic real-life community health workers, offering culturally and linguistically tailored information to users. They can communicate in English or Spanish and are available in diverse genders and racial\u002Fethnic backgrounds. vCHEs may be able to increase the enrollment of diverse participants into cancer clinical trials.",[54,25],"2026-08-07",{"date":320,"type":32},"2026-08-11",{"date":322,"type":32},"2025-05-20",{"date":324,"type":19},"2027-08-31",{"name":62,"class":39},{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":40},"100447598","complications-and-clinical-response-in-cancer-patients-treated-with-anti-vegf-related-therapies-100447598","NCT05108519","Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","A Prospective Study Evaluating Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies","Inclusion Criteria:\n\n* Patients must be able to understand and be willing to sign a written informed consent document\n* Patients must be receiving any anti-VEGF-related regimen in monotherapy or combination therapy",{"count":334,"type":19},170,"This study collects information about complications and clinical response in cancer patients treated with anti-VEGF-related therapies. This study aims to observe side effects that may happen to patients with advanced cancer who are treated with anti-VEGF related therapy. This may help doctors learn if there are any relationships between these side effects and how the disease may respond to treatment.",[24,25],{"date":280,"type":32},{"date":339,"type":32},"2019-04-08",{"date":246,"type":19},{"name":38,"class":39},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":48,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":354,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":358,"locationsCount":40},"100440986","the-impact-of-covid-19-on-pulmonary-procedures-100440986","NCT05022446","The Impact of COVID-19 on Pulmonary Procedures","The Impact of COVID-19 on Pulmonary Procedures: A Nationwide Survey","Inclusion Criteria:\n\n* Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and\u002For the American College of Chest Physicians (ACCP)\n* These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership\n\nExclusion Criteria:\n\nNone",{"count":350,"type":19},250,"This study investigates the changes in practice by pulmonary procedural programs across the United States as they faced the coronavirus pandemic. Information gathered from this study may help guide pulmonary programs on a wider scale and improve their practice. The study may also help researchers understand where they should focus research efforts to better respond to a pandemic in the future.",[353,24,25],"COVID-19 Infection",{"date":280,"type":32},{"date":356,"type":32},"2020-11-11",{"date":246,"type":19},{"name":38,"class":39},{"id":360,"slug":361,"hasResults":12,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":4,"eligibilityCriteria":365,"healthyVolunteers":48,"sex":16,"minAge":366,"maxAge":207,"enrollmentInfo":367,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":437},"100464928","collecting-blood-samples-from-patients-with-and-without-cancer-to-evaluate-tests-for-early-cancer-detection-100464928","NCT05334069","Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","Blinded Reference Set for Multicancer Early Detection Blood Tests","Inclusion Criteria:\n\n* Participants with a cancer diagnosis: Documentation of disease:\n\n  * Histologic documentation: Histologically confirmed diagnosis of invasive cancer\n  * Stage: Stage I-IV per American Joint Committee on Cancer (AJCC) 7th edition, with the exception of patients with leukemia, lymphoma, and multiple myeloma\n\n    * For leukemia: Type (chronic lymphocytic leukemia \\[CLL\\], chronic myeloid leukemia \\[CML\\], acute lymphoblastic lymphoma \\[ALL\\], acute myeloid leukemia \\[AML\\])\n    * For lymphoma: Stage I-IV based on Ann Arbor staging\n    * For multiple myeloma: Stage I, II, III based on Revised International Staging System (RISS)\n  * One of the following tumor types:\n\n    * Colorectal\n    * Bladder\n    * Head and neck\n    * Hepatobiliary\n    * Lung\n    * Lymphoma\n    * Leukemia\n    * Ovary \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Pancreas \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Multiple myeloma\n    * Gastric, esophageal or gastroesophageal\n    * Breast\n    * Thyroid\n    * Kidney\n\n      * For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Endometrium\n    * Prostate\n    * Melanoma\n\n      \\*\\*\\* For these specific cancer types only, patients may be enrolled prior to histologic confirmation of malignancy. Sites are required to contact the study chairs to review appropriateness for enrollment\n    * Sarcoma\n* Participants with a cancer diagnosis: No prior definitive systemic or local anti-cancer intervention\n* Participants with a cancer diagnosis: Age \\>= 40 and =\\\u003C 75\n* Participants with a cancer diagnosis: No known current pregnancy by self-report\n* Participants with a cancer diagnosis: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a cancer diagnosis: Willingness to provide blood samples for research use\n* Participants with a cancer diagnosis: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a cancer diagnosis: No history of organ transplantation\n* Participants with a cancer diagnosis: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants without a cancer diagnosis and without suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants without a cancer diagnosis and without suspicion of cancer: No known current pregnancy by self-report\n* Participants without a cancer diagnosis and without suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers)\n* Participants without a cancer diagnosis and without suspicion of cancer: Willingness to provide blood samples for research use\n* Participants without a cancer diagnosis and without suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants without a cancer diagnosis and without suspicion of cancer: No history of organ transplantation\n* Participants without a cancer diagnosis and without suspicion of cancer: Ability to read and comprehend English or Spanish\n\n  \\* Eligibility is restricted to individuals who can comprehend and read English or Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages\n* Participants with a high suspicion of cancer: High suspicion of ovarian cancer, pancreatic cancer, kidney cancer, or melanoma by clinical and\u002For radiological assessment, with plans for histologic or cytologic confirmation within 28 days after study blood draw\n\n  \\* Examples of highly suspicious cases include: elevated CA125 and abnormal transvaginal ultrasound, suspicious renal or pancreatic mass on imaging, suspicious cutaneous lesion concerning for melanoma\n* Participants with a high suspicion of cancer: Central review of radiology reports and\u002For clinical documentation conducted by study chairs\n* Participants with a high suspicion of cancer: Age \\>= 40 and =\\\u003C 75\n* Participants with a high suspicion of cancer: No known current pregnancy by self-report\n* Participants with a high suspicion of cancer: No known or prior history of in situ or invasive malignancy (excluding in situ non-melanoma skin cancers) other than the current cancer diagnosis\n* Participants with a high suspicion of cancer: Willingness to provide blood samples for research use\n* Participants with a high suspicion of cancer: Absence of medical contraindications to a research blood draw volume of 60 mL\n* Participants with a high suspicion of cancer: No history or organ transplantation\n* Participants with a high suspicion of cancer: Ability to read and comprehend English or Spanish \\* Eligibility is restricted to individuals who can comprehend and read English and Spanish given that participation in the study will require the ability to read and complete questionnaires that are available only in those two languages","40 Years",{"count":314,"type":19},"This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.",[370,371,372,373,374,375,376,377,378,379,24,380,381,382,25,26,383,384,385,386,27,387,388,389,390,391,392,393,394,395,396,397,398,399,400,401,402,403,404,405,406,407,408,409,410,411,412,413,414,415,416,417,418,419,420,421,422,423,424,425,426,427],"Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Ann Arbor Stage I Lymphoma","Ann Arbor Stage II Lymphoma","Ann Arbor Stage III Lymphoma","Ann Arbor Stage IV Lymphoma","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia","Gastroesophageal Junction Adenocarcinoma","Head and Neck Carcinoma","Invasive Breast Carcinoma","Kidney Carcinoma","Malignant Hepatobiliary Neoplasm","Muscle-Invasive Bladder Carcinoma","RISS Stage I Plasma Cell Myeloma","RISS Stage II Plasma Cell Myeloma","RISS Stage III Plasma Cell Myeloma","Stage I Bladder Cancer AJCC v6 and v7","Stage I Breast Cancer AJCC v7","Stage I Colorectal Cancer AJCC v6 and v7","Stage I Esophageal Cancer AJCC V7","Stage I Gastric Cancer AJCC V7","Stage I Lung Cancer AJCC v7","Stage I Ovarian Cancer AJCC v6 and v7","Stage I Pancreatic Cancer AJCC v6 and v7","Stage I Prostate Cancer AJCC v7","Stage I Uterine Corpus Cancer AJCC v7","Stage II Bladder Cancer AJCC v6 and v7","Stage II Breast Cancer AJCC v6 and v7","Stage II Colorectal Cancer AJCC v7","Stage II Esophageal Cancer AJCC v7","Stage II Gastric Cancer AJCC v7","Stage II Lung Cancer AJCC v7","Stage II Ovarian Cancer AJCC v6 and v7","Stage II Pancreatic Cancer AJCC v6 and v7","Stage II Prostate Cancer AJCC v7","Stage II Uterine Corpus Cancer AJCC v7","Stage III Bladder Cancer AJCC v6 and v7","Stage III Breast Cancer AJCC v7","Stage III Colorectal Cancer AJCC v7","Stage III Esophageal Cancer AJCC v7","Stage III Gastric Cancer AJCC v7","Stage III Lung Cancer AJCC v7","Stage III Ovarian Cancer AJCC v6 and v7","Stage III Pancreatic Cancer AJCC v6 and v7","Stage III Prostate Cancer AJCC v7","Stage III Uterine Corpus Cancer AJCC v7","Stage IV Bladder Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7","Stage IV Colorectal Cancer AJCC v7","Stage IV Esophageal Cancer AJCC v7","Stage IV Gastric Cancer AJCC v7","Stage IV Lung Cancer AJCC v7","Stage IV Ovarian Cancer AJCC v6 and v7","Stage IV Pancreatic Cancer AJCC v6 and v7","Stage IV Prostate Cancer AJCC v7","Stage IV Uterine Corpus Cancer AJCC v7","Thyroid Gland Carcinoma","2026-08-04",{"date":430,"type":32},"2026-08-05",{"date":432,"type":32},"2022-08-18",{"date":434,"type":19},"2027-02-28",{"name":436,"class":39},"Alliance for Clinical Trials in Oncology",744,{"id":439,"slug":440,"hasResults":12,"nctId":441,"briefTitle":442,"officialTitle":443,"acronym":4,"eligibilityCriteria":444,"healthyVolunteers":48,"sex":445,"minAge":49,"maxAge":4,"enrollmentInfo":446,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":40},"100136749","collecting-and-studying-blood-and-tissue-samples-from-patients-with-locally-recurrent-or-metastatic-prostate-or-bladderurothelial-cancer-100136749","NCT01050504","Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder\u002FUrothelial Cancer","Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy","Inclusion Criteria:\n\n* Patients with localized and\u002For metastatic bladder\u002Furothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured\n* Ability to adequately understand and give informed consent\n* Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for research or standard of care who are willing to donate archival tissue for this study\n* Alternatively, men and women without cancer or who are at risk of developing cancer are eligible to have blood or normal tissue collected if acquired; tissue will only be acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder; in patients without malignancy, no additional tissue beyond that necessary for care will be procured\n* Platelet count \\> 50,000\n* White blood cell (WBC) \\> 1,500\n* Hemoglobin (Hgb) \\> 8.0\n* International normalized ratio (INR) \\\u003C 1.5\n* Partial thromboplastin time (PTT) \\\u003C 45\n* No history of excessive unexplained bleeding from previous surgery\n\nExclusion Criteria:\n\n* Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days\n* Serious or uncontrolled infection\n* Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days","MALE",{"count":447,"type":19},1500,"This study collects and studies tissue and blood samples from patients with prostate or bladder\u002Furothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder\u002Furothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.",[450,25,451,452,453,454,455,456,417,457,425],"Localized Renal Pelvis and Ureter Urothelial Carcinoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Soft Tissues","Metastatic Renal Pelvis and Ureter Urothelial Carcinoma","Recurrent Bladder Carcinoma","Recurrent Prostate Carcinoma","Recurrent Renal Pelvis and Ureter Urothelial Carcinoma","Stage IV Bladder Urothelial Carcinoma AJCC v7",{"date":459,"type":32},"2026-08-06",{"date":461,"type":4},"2009-08",{"date":463,"type":19},"2029-01-31",{"name":465,"class":39},"University of Washington",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":98,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":40},"100614372","testing-an-educational-program-to-improve-goals-of-care-conversations-between-patients-and-their-care-teams-100614372","NCT07278739","Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams","A Randomized Controlled Trial of an Intervention Called \"Algorithm-Enabled Patients Activated in Cancer Care Through Teams\" (A-PACT) to Improve Goals of Care Communication for People With Cancer","Inclusion Criteria:\n\n* Participants must have a diagnosis of a solid tumor malignancy of any stage\n* Participants must be identified as high risk, defined as having 6 month mortality estimate from machine learning (ML) algorithm \\>= 20%\n* Participants must not be receiving or have pre-existing plans to enter hospice care at the time of study registration\n* Participant must be actively receiving or planning to receive systemic anti-cancer therapy (defined as any oral, injection, or intravenous therapy against cancer) within 3 months after registration\n\n  * NOTE: This includes chemotherapy (conventional or cytotoxic chemotherapy), hormone therapy, targeted therapy, and immunotherapy\n  * NOTE: Participants are allowed to be co-enrolled on other clinical trials including trials using investigational agents\n* Participants must be \\>= 18 years of age at the time of study enrollment\n* Participants who can complete Patient Reported Outcome (PRO) questionnaires in English or Spanish must be willing to 1) complete PROs at all scheduled assessments; and 2) complete the pre-registration (baseline) PRO forms within 14 days prior to registration\n* Participants must be able to provide a valid telephone number for the purpose of being contacted by the lay health worker\n* NOTE: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\n\n  * Patient and clinician participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines. This protocol does not permit use of Legally Authorized Representative NOTE: For this study, in the OPEN registration, clinician participants will be listed as their own treating investigator. However, clinician participants must not consent themselves or sign their own eligibility criteria forms",{"count":474,"type":19},1020,[121],"This clinical trial evaluates an educational program called Algorithm-Enabled Patients Activated in Cancer Care Through Teams (A-PACT) for reducing unplanned hospital visits and improving goals of care conversations with providers among patients with solid cancers. A-PACT is an educational program where lay health workers (educators) help patients talk with their health care team about issues that matter most to them (goals of care). During A-PACT sessions, patients receive assistance in formulating health care and end of life care preferences, assistance in completing advance directives, guidance on how to engage in these conversations with family members, friends, and clinical teams, and encouragement to discuss these topics with their clinical team. A-PACT may reduce unplanned hospital visits and improve goals of care communication with providers among patients with solid cancers.",[25],"2026-08-03",{"date":430,"type":32},{"date":481,"type":19},"2026-09-03",{"date":483,"type":19},"2032-07-21",{"name":485,"class":132},"SWOG Cancer Research Network",{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":490,"acronym":491,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":493,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":40},"100583786","investigating-memory-and-physical-activity-after-cancer-treatment-in-survivors-of-adolescent-and-young-adult-cancers-100583786","NCT06880861","Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers","IMPACT","Inclusion Criteria:\n\n* Adults (aged 18+ years)\n* Primary diagnosis of cancer when 15-39 years-old\n* Access to a desktop computer or laptop with reliable internet access\n* No gross motor impairments that prohibit ambulation\n* Willing to complete study requirements\n* English speaking\n\nExclusion Criteria:\n\n* Diagnosed with nonmelanoma skin cancer only\n* Not diagnosed with cancer in adolescent and young adult (AYA) age range of 15-39 years\n* Scheduled travel during the study period that is not indicative of individual's normal schedule",{"count":494,"type":19},150,"This study evaluates relationships among physical activity, thinking, and memory after cancer treatment in survivors of adolescent and young adult cancers.",[54,25],[498,499,500,501,502,503,504],"cancer","adolescent","young adult","cognition","memory","exercise","physical activity",{"date":428,"type":32},{"date":507,"type":32},"2025-07-01",{"date":509,"type":19},"2026-09-30",{"name":62,"class":39},{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":98,"phases":520,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":523,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":527,"locationsCount":40},"100522960","weighted-blanket-use-to-reduce-anxiety-in-oncology-patients-100522960","NCT06089408","Weighted Blanket Use to Reduce Anxiety in Oncology Patients","Weighted Blanket Use in Oncology Patients to Reduce Anxiety","Inclusion Criteria:\n\n* Age 18 years of age and older\n* About to begin either targeted or cytotoxic chemotherapy\n* Able to comprehend and sign a consent form\n* Able to read and complete surveys\n* Alert and oriented\n\nExclusion Criteria:\n\n* Currently using a weighted blanket at home\n* Non-English speaking\n* Peripheral neuropathy\n* Fibromyalgia\n* Open pressure ulcer\n* Recent surgical flap\n* Claustrophobic\n* Weight 45 kg or less",{"count":519,"type":19},114,[121],"This clinical trial compares the effect of using weighted blankets versus regular blankets during first time infusions (e.g. chemotherapy, targeted therapy etc.) to decrease adverse side effects such as anxiety and distress in cancer (oncology) patients. Feeling safe, comforted, and grounded in the world are some of the benefits noted by individuals who use weighted blankets. Deep touch pressure (DTP) has been found to reduce symptoms of stress and anxiety and is defined as a sensation one feels when being hugged, squeezed, or held. DTP affects the nervous system by creating a calming effect which may lower stress and increase feelings of well-being. The use of weighted blankets may help to manage anxiety and distress during chemotherapy or immunotherapy infusions.",[24,25],{"date":430,"type":32},{"date":525,"type":32},"2023-08-01",{"date":86,"type":19},{"name":528,"class":39},"Ohio State University Comprehensive Cancer Center",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":98,"phases":538,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":562},"100348403","phase-1-testing-an-immunotherapy-anti-cancer-drug-nivolumab-for-advanced-cancers-in-patients-with-autoimmune-disorders-aim-nivo-100348403","NCT03816345","Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO","A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)","Inclusion Criteria:\n\n* Patients can have either histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, or have a malignancy for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting, as well as the neoadjuvant or perioperative setting in which such treatment is considered standard of care or has been approved. Eligible tumor types include solid tumors and malignancies in which there is known evidence of clinical activity for single agent PD-1 or PD-L1 antibodies. Nivolumab or other PD1\u002FPD-L1 inhibitors are FDA-approved for the treatment of melanoma, non-small cell lung cancer (NSCLC), Merkel cell cancer, bladder cancer, renal cell carcinoma (RCC), gastric cancer, hepatocellular carcinoma (HCC), cervical cancer, head and neck cancer, Hodgkin lymphoma (HL), metastatic small cell lung cancer (SCLC), and any solid tumor with microsatellite instability (MSI)-high status confirmed. Patients with HL are eligible but must follow standard response criteria. Additional tumor types may be eligible on a case by case basis upon discussion with principal investigator (PI)\n\n  * Patients enrolling on the trial for adjuvant use will be restricted to those with histology for which a PD-1\u002FPD-L1 inhibitor has been approved in the adjuvant setting including but not limited to NSCLC, melanoma, RCC, cervical cancer, and bladder cancer\n  * Patients enrolled on the study can receive Nivolumab with other FDA-approved combinations according to the FDA package insert, including, but not limited to ipilimumab, cabozantinib or chemotherapy\n* Patients who have previously received other forms of immunotherapy (high-dose \\[HD\\] IL-2, IFN, CTLA-4) are allowed. Patients must not have received cytokine immunotherapy for at least 4 weeks before nivolumab administration. Patients who have received prior anti-CTLA4 will be allowed and the washout period is 6 weeks\n* Age \\>= 18 years; children are excluded from this study but may be eligible for future pediatric phase 1 combination trials\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 (Karnofsky \\>= 60)\n* Life expectancy of greater than 12 weeks\n* Leukocytes \\>= 1,000\u002FmcL\n* Absolute neutrophil count \\>= 500\u002FmcL\n* Platelets \\>= 50,000\u002FmcL\n* Total bilirubin =\\\u003C 2 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 5 x institutional ULN or =\\\u003C 8 x institutional ULN for patients with liver metastases or an autoimmune disease that is contributing to the elevation of these values\n* Creatinine ULN OR glomerular filtration rate (GFR) \\>= 30 mL\u002Fmin (if using the Cockcroft-Gault formula)\n* Human immunodeficiency virus (HIV)-infected patients on effective antiretroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* If evidence of chronic hepatitis B virus (HBV) infection, HBV viral load must be undetectable on suppressive therapy if indicated\n* If history of hepatitis C virus (HCV) infection, must be treated with undetectable HCV viral load\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate central nervous system (CNS) specific treatment is not required and is unlikely to be required for at least 4 weeks (or scheduled assessment after the first cycle of treatment), and a risk-benefit analysis (discussion) by the patient and the investigator favors participation in the clinical trial\n* The effects of nivolumab on the developing human fetus are unknown. For this reason, women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 5 months after the last dose of investigational product. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose of investigational product\n\n  * Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\n  * WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy), tubal ligation, or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU\u002FmL\n  * These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days, and men who are sexually active with WOCBP use contraception for 5 half-lives plus 90 days\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately. Patients can resume treatment upon termination of a pregnancy or the completion of a successful pregnancy\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients with more than one autoimmune disease are eligible. The treating physician would determine which autoimmune disease is dominant and the patient would be treated under that specific cohort (Please note: Patients with more than one autoimmune disease should receive assessments for all previously diagnosed autoimmune diseases. For example, a patient with psoriasis and IBD might be enrolled in the IBD cohort. Disease assessments for both psoriasis and IBD should be obtained, as per protocol. Case report forms \\[CRFs\\] for all relevant autoimmune diseases should be utilized. However, all additional cohort requirements will be considered optional and only the assessments from the assigned cohort will be considered mandatory)\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients with known SSc or DM according to updated classification criteria (Van den Hoogan et al., Arthritis Rheum 2013;65(11):2737-47; Lundberg et al., A\\&R in press). Overlap features are permitted, but patients must meet criteria for a \"primary diagnosis\" of DM or SSc\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for DM or SSc unless specifically excluded\n* DM\u002FSSc-SPECIFIC INCLUSION: Patients must have a baseline computed tomography (CT) of the chest (within 6 months of study entry)\n* RA-SPECIFIC INCLUSION: Rheumatologist-diagnosed RA requiring prior treatment with disease-modifying antirheumatic drugs (DMARDs) before patient was diagnosed with current malignancy. We recommend, but do not require, documentation for meeting 2010 American College of Rheumatology (ACR)\u002FEuropean League Against Rheumatism (EULAR) classification criteria for RA\n* RA-SPECIFIC INCLUSION: Prednisone up to 10 mg\u002Fday will be allowed. Intraarticular steroids will be allowed for the treatment of new symptomatic joints\n* RA-SPECIFIC INCLUSION: Nonsteroidal anti-inflammatory drugs (NSAIDs) will be allowed\n* SLE-SPECIFIC INCLUSION: SLE diagnosed by a rheumatologist. The patient should meet the revised 1997 American College of Rheumatology (ACR) classification criteria for SLE, but this is not mandatory\n* ULCERATIVE COLITIS (UC)-SPECIFIC INCLUSION: Diagnosis of UC must be made by endoscopy with biopsies\n* UC-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* UC-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (antigen \\[Ag\\] negative, antibody \\[core (c)Ab\\] negative, antibody \\[surface (s)Ab\\] positive or negative) and Mycobacterium tuberculosis (purified-protein- derivative \\[PPD\\] or enzyme-linked immunospot assay \\[ELISpot or T-spot\\]) or be on appropriate anti-microbial treatment for these infections\n* UC-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission, defined as a Mayo Clinic score (MCS) of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 either without medications, or treated with 5-ASA derivative, probiotic, or prior fecal transplant\n* UC-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on 6-mercaptopurine, azathioprine, methotrexate, or rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* UC-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either be A) in clinical remission, defined as a MCS of 2 or lower and no subscore higher than 1, and an endoscopic subscore of 0 or 1 on a biologic therapy targeting tumor necrosis alpha (TNF-α) (infliximab, adalimumab, golimumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease defined as a MCS of 3-5 and no subscore higher than 2, and an endoscopic subscore of \\\u003C 2 on one of the medications or combination of medications defined for the Moderate or Mild cohort\n* CROHN'S DISEASE (CD)-SPECIFIC INCLUSION: Complete colonoscopy with biopsies during study screening, within 8 weeks before initial nivolumab administration, or within 4 weeks after initial nivolumab administration\n* CD-SPECIFIC INCLUSION: If patients have prior known disease in the stomach or small intestines, appropriate endoscopic evaluation (esophagogastroduodenoscopy\u002Fvideo capsule endoscopy) and\u002For imaging (computed tomography or magnetic resonance enterography) must also be current within 4 weeks prior to nivolumab administration\n* CD-SPECIFIC INCLUSION: Deep enteroscopy techniques, such as double balloon enteroscopy, will not be required\n* CD-SPECIFIC INCLUSION: Patients must test negative for hepatitis B (sAg negative, cAb negative, sAb positive or negative) and M. tuberculosis (PPD or ELISpot or T-spot) or be on appropriate anti-microbial treatment for these infections\n* CD-SPECIFIC INCLUSION: Mild Disease Cohort: Patients must be in clinical remission as defined by a Crohn's Disease Activity Index (CDAI) \\\u003C 150 either without treatment or on a 5-ASA derivative, probiotic, antibiotics, or following fecal transplant\n* CD-SPECIFIC INCLUSION: Moderate Disease Cohort: Patients must be in clinical remission as defined by a CDAI \\\u003C 150 on 6-mercaptopurine, azathioprine, methotrexate, rectal hydrocortisone, budesonide, or one of these medications in combination with any of the medications listed in the Mild cohort\n* CD-SPECIFIC INCLUSION: Severe Disease Cohort (A or B): Patients must either A) be in clinical remission as defined by a CDAI \\\u003C 150 on biologic therapy targeting TNF-α (infliximab, adalimumab, certolizumab pegol), IL-12\u002F23p40 (ustekinumab), α4β7 integrin (vedolizumab), or one of these biologic therapies in combination with any of the medications listed in the Mild or Moderate cohort, or B) have mild active disease as defined by a CDAI of 150 to 220 on one of medications or combination of medications defined for the Moderate or Mild cohort\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For other autoimmune diseases that cannot be classified, the eligibility criteria will be determined by the managing rheumatologist or other autoimmune disease specialist, based on the clinical judgement and current American College of Radiology (ACR) classification guidelines or other relevant guidelines, as per the disease category in question\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For giant cell arteritis (GCA), patients must have had positive temporal artery biopsy for GCA and abnormal erythrocyte sedimentation rate (ESR) at time of diagnosis\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: For polymyalgia rheumatica (PMR), patients must have clinical diagnosis in addition to elevated inflammatory markers including (ESR, C reactive protein \\[CRP\\])\n* OTHER AUTOIMMUNE DISEASES- NS-SPECIFIC INCLUSION: Patients can be in remission (with no glucocorticoids or immunosuppressive medications) or have low-moderate activity, which is defined as being on prednisone ≤ 10 mg or equivalent\n* MS-SPECIFIC INCLUSION: Patients must meet 2017 McDonald criteria for the diagnosis of MS (Thompson AJ, et al. Diagnosis of multiple sclerosis: 2017 revision of the McDonald criteria. Lancet Neurol. 17(2):162-173.)\n* MS-SPECIFIC INCLUSION: Patients with MS can be in remission and can have a history of being on immunomodulatory agents, but at the time of entry into the clinical trial, patients should be off any concurrent MS therapy for at least 2 weeks. Patients receiving concomitant interferon gamma (IFN-γ treatment) will be permitted in the study\n* SJS-SPECIFIC INCLUSION: SjS diagnosed by a rheumatologist or oral medicine provider. The patient should meet the American-European Consensus Criteria for Sjögren's Syndrome (Vitali, et al., 2002). If on treatment, the patient may only be on hydroxychloroquine and prednisone ≤ 10 mg or equivalent\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients with known PsO as diagnosed by a dermatologist or PsA by a rheumatologist and\u002For by Classification for Psoriatic Arthritis (CASPAR) criteria (Tillett et al., 2012)\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients must have stable disease as determined by the investigator with no change in systemic therapy and\u002For biologic therapy for at least 3 months, except for those on tumor necrosis factor (TNF) inhibitors. In the case of TNF inhibition, patients may have transitioned to an alternative biologic therapy with stable disease for at least 4 weeks. For PsA, no change in corticosteroid therapy for at least 1 month prior to baseline and dose must be 10 mg or less\n* PSO\u002FPSA-SPECIFIC INCLUSION: Patients may be on any concurrent therapy for PsO or PsA unless specifically excluded\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than 4 weeks earlier have not resolved or stabilized. Palliative (limited-field) radiation therapy (RT) is permitted (2 week washout from start of treatment), if all of the following criteria are met:\n\n  * Repeat imaging demonstrates no new sites of bone metastases\n  * The lesion being considered for palliative radiation is not a target lesion\n* Patients with prior therapy with an anti-PD-1 or anti-PD-L1\n* Patients with prior allogeneic hematologic transplant\n* Patients who are receiving any other anticancer investigational agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* UC-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* UC-SPECIFIC EXCLUSION: Prior colectomy\n* UC-SPECIFIC EXCLUSION: Concurrent primary sclerosing cholangitis (PSC). Patients with PSC can be enrolled on the Other Autoimmune Diseases Cohorts\n* UC-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* CD-SPECIFIC EXCLUSION: Known untreated abscesses, untreated and symptomatic strictures, short gut physiology, or isolated jejunal disease\n* CD-SPECIFIC EXCLUSION: Patients who have received ipilimumab treatment\n* CD-SPECIFIC EXCLUSION: Patients on empiric immunosuppressive treatment without any clinical workup\n* MS-SPECIFIC EXCLUSION: Patients with MS cannot have medical contraindications to gadolinium-enhanced magnetic resonance imaging (MRI)",{"count":537,"type":19},300,[539],"PHASE1","This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced), to other places in the body (metastatic) or cannot removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Cabozantinib is a type of tyrosine kinase inhibitor and a type of angiogenesis inhibitor. Chemotherapy drugs, such as platinum containing therapies and fluoropyrimidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab alone and in combination with other treatments, including ipilimumab, cabozantinib, platinum containing therapy, or fluoropyrimidine, may be safe, tolerable, and\u002For effective in treating patients with autoimmune disorders and advanced, metastatic, or unresectable cancer.",[542,543,544,24,545,25,546,547,548,549,550,551,552,553],"Autoimmune Disease","Crohn Disease","Dermatomyositis","Inflammatory Bowel Disease","Multiple Sclerosis","Psoriasis","Psoriatic Arthritis","Rheumatoid Arthritis","Sjogren Syndrome","Systemic Lupus Erythematosus","Systemic Scleroderma","Ulcerative Colitis","2026-07-30",{"date":556,"type":32},"2026-07-31",{"date":558,"type":32},"2019-07-16",{"date":560,"type":19},"2028-03-30",{"name":157,"class":158},52,{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":4,"eligibilityCriteria":569,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":570,"targetDuration":4,"studyType":98,"phases":572,"briefSummary":573,"conditions":574,"keywords":577,"overallStatus":191,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":40},"100648592","symptom-management-to-improve-completion-of-patient-reported-outcome-measures-100648592","NCT07723495","Symptom Management to Improve Completion of Patient-reported Outcome Measures","Promoting Patient Reporting of Outcome Measures Through Technology Integrated Self-management and Engagement (PROMISE)","Inclusion Criteria:\n\n* 1\\) Adults (≥18 years) with a diagnosis of a malignancy of head and neck or lung cancers.\n* 2\\) Scheduled to start infusion systemic therapy in the next 4 weeks or have started infusion systemic therapy in the past 4 weeks.\n* 3\\) Able to read and understand English.\n* 4\\) Cognitively oriented to person, place and time (determined by recruiter).\n\nExclusion Criteria:\n\n* 1\\) Unable to read and understand English.",{"count":571,"type":19},78,[121],"In this clinical trial, patient reported outcome (PRO) assessment completion is compared between patients (undergoing systemic therapy for head and neck or lung cancer) who receive additional symptoms monitoring and evidence-based self-management strategies for those with elevated symptoms (intervention arm), and those who do not receive these (control arm). PRO measures are validated tools that capture health-related perspectives directly from the patient and are complementary to provider assessment. Timely completion of PRO assessments and symptoms management of moderate or severe symptoms are essential to improve quality of life and decrease unwanted health care utilization. However, only \\~40% of patients complete PRO assessments in clinical settings. In addition, systemic therapy for cancer results in many symptoms (e.g., dry mouth, shortness of breath, constipation) not covered by the disease-general Patient-Reported Outcomes Measurement Information System (PROMIS) measures. Patients in the control arm will receive the existing PROMIS assessments and a thank you message upon completion. Patients in the intervention arm will receive the PROMIS assessments in addition to nine Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) most prevalent symptoms, and evidence-based self-management strategies Handbook for those with elevated symptoms. Patients in the intervention arm will enter their symptoms in a SMS text and they will be directed to the handbook for strategies to manage their elevated symptoms using a digital platform-Computerized Intervention Authoring System (CIAS)-integrated within the Epic electronic health records. Information gathered has the potential to influence cancer care practices on a larger scale, shaping policies and clinical practices to improve health outcomes for cancer patients and reducing the burden of cancer-related symptoms.",[25,575,576],"Malignant Head and Neck Neoplasm","Malignant Lung Neoplasm",[578,579,580],"Cancer","Symptom management","Patient-reported outcomes","2026-07-28",{"date":583,"type":32},"2026-07-29",{"date":585,"type":19},"2027-10-01",{"date":587,"type":19},"2031-09-01",{"name":589,"class":39},"Henry Ford Health System",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":98,"phases":599,"briefSummary":600,"conditions":601,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":620,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":40},"100614857","phase-2-the-cancer-connected-access-and-remote-expertise-beyond-walls-program-to-provide-in-home-cancer-treatment-and-improve-treatment-satisfaction-in-cancer-patients-living-in-the-florida-panhandle-and-surrounding-areas-100614857","NCT07285044","The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas","Cancer CARE (Connected Access and Remote Expertise) Beyond Walls - Pilot, Phase 2 Clinical Trial to Evaluate Administration of Cancer-Directed Therapy in the Patient's Homes Versus in Clinic in the Florida Panhandle and Surrounding Areas","Inclusion Criteria:\n\n* Patient has had adequate tolerability of their clinical standard of care treatment, in the opinion of their treating physician, and no clinically significant drug-related reactions occurred prior to consent\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) Food and Drug Administration (FDA)-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. National Comprehensive Cancer Network \\[NCCN\\], American Society of Clinical Oncology \\[ASCO\\], American Society of Hematology \\[ASH\\], etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines\n* A social stability screener, used per standard of care, indicates patient is appropriate to participate in the CCBW program\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, 2 or 3 at the discretion of the treating physician\n* Female or male patients age \\>= 18 years at the time of consent\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Patients with histologically confirmed malignancy who are currently receiving treatment with one of the eligible treatment regimens. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis alone: histologic confirmation is not required.\n\n  * Note: patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving hormonal or immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Co-administration with hormonal agents such as anti-androgens, poly(ADP-ribose) polymerase (PARP) inhibitors, oral gonadotrophin releasing hormone (GnRh) antagonists, estrogens, selective estrogen receptor modulators (SERMs), or aromatase inhibitors are allowed, however combinations of oral regimens only are not permitted. Patients may receive any combination of any listed medications or regimens\n  * Eligible disease cancer types:\n\n    * Amyloidosis\n    * Basal cell carcinoma\n    * Biliary\n    * Bladder\n    * Breast\n    * Cervical\n    * Colorectal\n    * Endometrial\n    * Fallopian tube\n    * Gastroesophageal\n    * Glioblastoma\n    * Head and neck\n    * Hepatocellular\n    * Hodgkin lymphoma\n    * Lung\n    * Mantle cell lymphoma\n    * Merkle cell carcinoma\n    * Multiple myeloma\n    * Melanoma\n    * Myelodysplastic syndrome\n    * Ovarian\n    * Pancreatic\n    * Peritoneal\n    * Prostate\n    * Renal cell carcinoma\n    * Squamous cell carcinoma\n    * Urothelial carcinoma\n  * Eligible regimens\n\n    * Atezolizumab +\u002F- bevacizumab\n    * Avelumab\n    * Bevacizumab\n    * Bortezomib\n    * Cemiplimab\n    * Daratumumab +\u002F- bortezomib\n    * Darbepoetin alpha\n    * Degarelix\n    * Denosumab (Xgeva)\n    * Durvalumab\n    * Fluorouracil +\u002F- bevacizumab\n    * Fulvestrant\n    * Goserelin\n    * Ipilimumab +\u002F- Nivolumab\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + relatlimab\n    * Octreotide\n    * Pembrolizumab\n    * Pertuzumab +\u002F- trastuzumab\n    * Trastuzumab +\u002F- pertuzumab\n    * Zoledronic acid (Zometa)\n* Willingness to follow birth control requirements for females and males of reproductive potential\n* Resides within the Florida Panhandle and surrounding area serviced by the at-home healthcare supplier utilized for the study and a paramedic network\n* Patient's residence has an existing Wi-Fi connection or can be connected using using a mobile Wi-Fi device provided as part of the program so as to enable a reliable connection with the remote CCBW Command Center at Mayo Clinic\n* Patients who, according to documentation from their treating provider, plan to continue the eligible treatment regimen they are currently prescribed for \\>= 12 weeks from the time of registration\n* Provide written informed consent\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)\n\nExclusion Criteria:\n\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Receiving any investigational agent which would be considered as a treatment for the primary neoplasm.\n\n  * Note: oral concomitant medications for oncologic indications will be maintained per standard of care treatment and not considered part of the trial. Any nononcologic medication, regardless of route of administration will be maintained per standard of care treatment and also not considered part of the trial; therefore, patients receiving oral anti-cancer or other medications per standard of care treatment in addition to any of the medications listed are considered eligible for this trial\n* Individuals who require continuous (24\u002F7) assistance with daily living and are unable to independently manage the technology required for study participation, unless a caregiver is available and willing to provide consistent support throughout the study\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)",{"count":598,"type":19},27,[144],"This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.",[602,603,604,213,214,605,215,606,607,608,609,379,54,610,611,219,25,612,26,613,614,615,220,221,616,222,617,618,619],"Amyloidosis","Basal Cell Carcinoma","Biliary Tract Carcinoma","Cervical Carcinoma","Endometrial Carcinoma","Fallopian Tube Carcinoma","Gastroesophageal Junction Carcinoma","Glioblastoma","Hepatocellular Carcinoma","Hodgkin Lymphoma","Mantle Cell Lymphoma","Merkel Cell Carcinoma","Multiple Myeloma","Myelodysplastic Syndrome","Primary Peritoneal Carcinoma","Renal Cell Carcinoma","Squamous Cell Carcinoma","Urothelial Carcinoma",{"date":554,"type":32},{"date":622,"type":32},"2025-12-18",{"date":624,"type":19},"2026-12-18",{"name":62,"class":39},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":98,"phases":634,"briefSummary":635,"conditions":636,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":637,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":641,"locationsCount":40},"100559836","genetic-testing-for-the-prevention-of-cancer-in-american-indian-communities-juniper-trial-100559836","NCT06569316","Genetic Testing for the Prevention of Cancer in American Indian Communities (JUNIPER Trial)","Journey to Understanding - American Indian Peoples Engagement in Cancer Research Arizona (JUNIPER)","Inclusion Criteria:\n\n* Male or female adults \\>= 18 years of age\n* Cancer patient undergoing active treatment or a cancer survivor\n* Self-identify as American Indian\n\nExclusion Criteria:\n\n* Unable to provide informed consent\n* Individuals who are under 18 years of age\n* Prisoners",{"count":537,"type":19},[121],"This clinical trial is studying the genetic changes in cells associated with different types of cancer in American Indian (AI) populations in the Southwest to improve cancer screening, precision prevention, and therapeutic intervention for individual in these communities. AI tribes have much lower rates of cancer screening, have more limited access to healthcare, are more often diagnosed at later stages of disease, and have the poorest outcomes in all types of cancer when compared to any other racial and ethnic group in the United States. Due to these significant cancer health disparities, AIs have been understudied and little is known about the molecular characterization of tumors arising in AIs. Undergoing genetic testing of tumors may improve cancer outcomes in AI participants and communities.",[54,25],{"date":583,"type":32},{"date":639,"type":32},"2024-09-27",{"date":324,"type":19},{"name":62,"class":39}]